DK1231840T3 - Anti-angiogent cellulært middel til cancerterapi - Google Patents

Anti-angiogent cellulært middel til cancerterapi

Info

Publication number
DK1231840T3
DK1231840T3 DK00987995T DK00987995T DK1231840T3 DK 1231840 T3 DK1231840 T3 DK 1231840T3 DK 00987995 T DK00987995 T DK 00987995T DK 00987995 T DK00987995 T DK 00987995T DK 1231840 T3 DK1231840 T3 DK 1231840T3
Authority
DK
Denmark
Prior art keywords
cancer therapy
cellular agent
angiogenic
angiogenic cellular
agent
Prior art date
Application number
DK00987995T
Other languages
English (en)
Inventor
Ernest G Hope
Original Assignee
Red Cliff Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Cliff Holding filed Critical Red Cliff Holding
Application granted granted Critical
Publication of DK1231840T3 publication Critical patent/DK1231840T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00987995T 1999-11-24 2000-11-22 Anti-angiogent cellulært middel til cancerterapi DK1231840T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16751399P 1999-11-24 1999-11-24
PCT/US2000/032322 WO2001037671A1 (en) 1999-11-24 2000-11-22 Anti-angiogenic cellular agent for cancer therapy

Publications (1)

Publication Number Publication Date
DK1231840T3 true DK1231840T3 (da) 2009-11-23

Family

ID=22607682

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00987995T DK1231840T3 (da) 1999-11-24 2000-11-22 Anti-angiogent cellulært middel til cancerterapi

Country Status (10)

Country Link
US (3) US20080260701A1 (da)
EP (1) EP1231840B1 (da)
JP (1) JP2003519473A (da)
AU (1) AU2425801A (da)
CA (1) CA2391434A1 (da)
DE (1) DE60042606D1 (da)
DK (1) DK1231840T3 (da)
ES (1) ES2383418T3 (da)
PT (1) PT1231840E (da)
WO (1) WO2001037671A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057580A2 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
US8877182B2 (en) 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
EP3018200A1 (en) * 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
CN106987558B (zh) * 2017-05-31 2019-12-20 东莞市保莱生物科技有限公司 一种cik细胞培养基
CN108853143A (zh) * 2018-07-04 2018-11-23 盛春华 治疗银屑病的免疫细胞制剂、其制备方法及应用
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173225A (en) * 1990-05-07 1992-12-22 Bowolfe, Inc. Method for making ultra-thin dense skin membrane
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1999046365A1 (en) * 1998-03-12 1999-09-16 Emory University Methods and compositions for the selective expansion of gamma/delta t-cells
PT1107789E (pt) * 1998-08-24 2008-10-08 Univ Leland Stanford Junior Composições e métodos para proteger órgãos, tecidos e células de danos mediados pelo sistema imunitário

Also Published As

Publication number Publication date
CA2391434A1 (en) 2001-05-31
US20080260701A1 (en) 2008-10-23
DE60042606D1 (de) 2009-09-03
US20080248002A1 (en) 2008-10-09
JP2003519473A (ja) 2003-06-24
ES2383418T3 (es) 2012-06-21
EP1231840A1 (en) 2002-08-21
AU2425801A (en) 2001-06-04
US20100087001A1 (en) 2010-04-08
PT1231840E (pt) 2009-10-26
EP1231840A4 (en) 2004-09-29
WO2001037671A1 (en) 2001-05-31
EP1231840B1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
LTPA2020503I1 (lt) Rapamicino darinys, skirtas kasos vėžio gydymui
EP1196852A4 (en) Headend provisioning agent
EP1472614A4 (en) MOBILE-TYPE NAVIGATION ACCELERATOR SYSTEM
DE50214044D1 (de) Heterogenes mobilfunksystem
DK1690550T3 (da) Terapeutisk middel til mesothelioma
DK1355904T3 (da) Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
DK1176964T3 (da) Brug af ET743 til behandling af cancer
FR2828540B1 (fr) Support antivibratoire hydraulique
DE60016868D1 (de) Notrutsche
DK1231840T3 (da) Anti-angiogent cellulært middel til cancerterapi
FR2831236B1 (fr) Support antivibratoire hydraulique
FR2822911B1 (fr) Support antivibratoire hydraulique
NO20021976D0 (no) Selektiv leverterapi
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
NO20034356D0 (no) Terapeutisk middel for overaktiv bl¶re
DK1020430T3 (da) Middel indeholdende L-carnitin
NO20024077L (no) Bifunksjonelt chelaterende middel
FI990183A0 (fi) Solukkoradiojärjestelmä
NO20020044D0 (no) Terapeutisk middel for legemiddel-resistent hypercalcemi
FR2828541B1 (fr) Support antivibratoire hydraulique
FIU990492U0 (fi) Kännykkä
SE9902303D0 (sv) Perpeteum mobile
NO990619D0 (no) Perpetum mobile
ES1043806Y (es) Soporte movil perfeccionado para andamios.